(Q34900399)

5 August 2017

1 reference

title

Isavuconazole: a new and promising antifungal triazole for the treatment of invasive fungal infections (English)

1 reference

invasive fungal infections

5 August 2017

main subject

1 reference

Emilio Bouza

2

0 references

author name string

Jesús Guinea

series ordinal

1

1 reference

5 August 2017

publication date

1 December 2008

1 reference

5 August 2017

number of pages

13

1 reference

based on heuristic

inferred from page(s)

published in

Future Microbiology

1 reference

5 August 2017

volume

3

1 reference

5 August 2017

issue

6

1 reference

5 August 2017

page(s)

603-615

1 reference

Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors.

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.6.603

Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.6.603

Epidemiology of invasive candidiasis: a persistent public health problem

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.6.603

Changing epidemiology of systemic fungal infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.6.603

Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.6.603

Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.6.603

Workload due to Aspergillus fumigatus and significance of the organism in the microbiology laboratory of a general hospital.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.6.603

Invasive aspergillosis in the ICU: an emerging disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.6.603

Invasive aspergillosis in the intensive care unit

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.6.603

Newer systemic antifungal agents : pharmacokinetics, safety and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.6.603

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.6.603

Lipid formulations of amphotericin B: recent progress and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.6.603

Lipid formulations of amphotericin B: clinical efficacy and toxicities

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.6.603

Liposomal amphotericin B: clinical experience and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.6.603

A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.6.603

Design, synthesis and antifungal activity of a novel water soluble prodrug of antifungal triazole

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.6.603

In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.6.603

Evaluation of Etest method for determining isavuconazole MICs against Cryptococcus gattii and Cryptococcus neoformans.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.6.603

In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.6.603

In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.6.603

Activity of BAL 4815 against filamentous fungi

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.6.603

In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.6.603

Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated Aspergillus flavus

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.6.603

Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in h

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.6.603

Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.6.603

Anidulafungin versus fluconazole for invasive candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.6.603

Comparison of caspofungin and amphotericin B for invasive candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.6.603

Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.6.603

Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.3.6.603

21 January 2018

Identifiers

DOI

10.2217/17460913.3.6.603

1 reference

release_sd6whavl7nflbkoz475fdhykpa

5 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/sd6whavl7nflbkoz475fdhykpa

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference